REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

The clinical trial for del 5q MDS was an open label, single-arm, multicenter phase 2 trial (N=148)1

Studied in transfusion-dependent anemia in patients with IPSS lower-risk del 5q MDS with or without additional abnormalities.1

Go to Trial Design

Learn about the baseline demographics of patients in the del 5q MDS clinical trial.

See Baseline Characteristics

Choose REVLIMID first for transfusion-dependent anemia in patients with low- or intermediate-1–risk del 5q MDS.1

Explore Efficacy Data

Learn about the hematologic adverse reactions reported in ≥5% of lenalidomide-treated patients.1

Go to Safety

Find out how your patients compare to the patients in the REVLIMID del 5q MDS study.

Learn About the Trial Design